Community Health Network

Futó vizsgálatok

• Toboroz

  FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

  NCT07446322· 2. fázis· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· 3. fázis· Forrás

• Toboroz

  A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

  NCT07027514· 1. fázis· Forrás

• Toboroz

  A Study of LY4175408 in Participants With Advanced Cancer

  NCT07046923· 1. fázis· Forrás

• Toboroz

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Forrás

• Toboroz

  A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  NCT06785636· 1/2. fázis· Forrás

• Toboroz

  A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

  NCT06663319· 1. fázis· Forrás

• Toboroz

  A Study of VET3-TGI in Patients With Solid Tumors

  NCT06444815· 1. fázis· Forrás

• Fut, nem toboroz

  MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06586515· 1. fázis· Forrás

• Toboroz

  Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  NCT06324357· 1/2. fázis· Forrás

• Fut, nem toboroz

  S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP

  NCT06188702· 1/2. fázis· Forrás

• Toboroz

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· 1/2. fázis· Forrás

• Toboroz

  A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

  NCT05902988· 1/2. fázis· Forrás

• Toboroz

  I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

  NCT05733520· Forrás

• Fut, nem toboroz

  A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension

  NCT05203510· 4. fázis· Forrás

• Toboroz

  GEMINI-NSCLC: NSCLC Biomarker Study

  NCT05236114· Forrás

• Toboroz

  First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

  NCT05216432· 1. fázis· Forrás

• Fut, nem toboroz

  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

  NCT04956640· 1/2. fázis· Forrás

• Fut, nem toboroz

  Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  NCT04666038· 3. fázis· Forrás

• Toboroz

  A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  NCT04657068· 1/2. fázis· Forrás

• Toboroz

  Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  NCT04068597· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  NCT03522246· 3. fázis· Forrás

• Toboroz

  The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

  NCT03142152· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák6 toboroz
• Vastagbélrák6 toboroz
• Gyomor- és nyelőcsőrák3 toboroz
• Hasnyálmirigyrák3 toboroz
• Méhtestrák3 toboroz
• Petefészekrák3 toboroz
• Áttétes emlőrák2 toboroz
• Fej-nyaki daganatok2 toboroz
• Tripla negatív emlőrák2 toboroz
• Akut mieloid leukémia (AML)1 toboroz
• Alzheimer-kór1 toboroz
• Hólyagrák1 toboroz
• Magas vérnyomás1 toboroz
• Méhnyakrák1 toboroz
• Melanóma1 toboroz
• Mezotelióma1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Prosztatarák1 toboroz
• Pulmonális artériás hipertónia1 toboroz
• Szívelégtelenség1 toboroz
• Vesedaganat1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  Umbrella Study for Analysis of Data Related to Patients With Cancer

  NCT06018753· Forrás

• Leállították

  Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

  NCT05860296· 1/2. fázis· Forrás

• Lezárult

  A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

  NCT05668585· 1. fázis· Forrás

• Leállították

  Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

  NCT05169437· 2. fázis· Forrás

• Lezárult

  A Study of SEA-CD40 Given With Other Drugs in Cancers

  NCT04993677· 2. fázis· Forrás

• Lezárult

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· 3. fázis· Forrás

• Lezárult

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· 3. fázis· Forrás

• Lezárult

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· 2. fázis· Forrás

• Lezárult

  A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

  NCT02428712· 1/2. fázis· Forrás

• Lezárult

  LOWER: Lomitapide Observational Worldwide Evaluation Registry

  NCT02135705· Forrás